Kornimate/medical-research-clean huggingface dataset:
low dose computed tomography for lung cancer screening

Conditions: Smoking

Summary: this study will evaluate the impact of a proactive, ehr-supported enrollment strategy that links ldct-eligible smokers with an evidence-based intervention comprised of a web-based program and integrated text messaging. the goal is to provide actionable findings about how to most effectively and cost efficiently promote abstinence in ldct clinics.

using a 3-arm randomized trial design with repeated measures at 1, 3, 6, and 12 months, the study will randomize n=1650 smokers who present for ldct lung cancer screening to an passive referral usual care control condition, proactive referral to a digital cessation intervention that combines web and text messaging, or proactive referral to a digital cessation intervention combined with tobacco treatment specialist counseling. the study will examine overall effectiveness of the interventions in promoting abstinence, the impact of proactive referral to treatment, and the total cost and cost effectiveness of the interventions. the study will also examine the representativeness of the enrolled sample and explore barriers and facilitators to intervention adoption with ldct clinic leaders. the trial is structured as a practical clinical trial to answer key questions of direct relevance to ldct decision-makers.

Eligibility criteria:
inclusion criteria: 1. scheduled for ldct screening 2. current smoking (every day/some days) 3. at least weekly use of the internet 4. current ownership of cell phone with a text messaging plan 5. willing to receive study text messages. 6. ability to complete all aspects of the study 7. ability to provide signed informed consent exclusion criteria: 1. current (in the past 30 days) use of tobacco cessation medication or participation in tobacco cessation treatment. 2. those with a condition deemed by the investigators to be exclusionary to the study

Keywords: tobacco smoking low dose computed tomography lung screening text messaging
apol1 long-term kidney transplantation outcomes network (apollo)

Conditions: Kidney Diseases; Kidney Failure; Kidney Disease, Chronic

Summary: the apollo study is being done in an attempt to improve outcomes after kidney transplantation and to improve the safety of living kidney donation based upon variation in the apolipoprotein l1 gene (apol1). genes control what is inherited from a family, such as eye color or blood type. variation in apol1 can cause kidney disease. african americans, afro-caribbeans, hispanic blacks, and africans are more likely to have the apol1 gene variants that cause kidney disease. apollo will test dna from kidney donors and recipients of kidney transplants for apol1 to determine effects on kidney transplant-related outcomes.

the national institutes of health (nih)-sponsored collaborative apol1 long-term kidney transplantation outcomes network (apollo) is charged with prospectively assessing the effects of renal-risk variants (rrvs) in the apolipoprotein l1 gene (apol1) on outcomes for kidneys from donors with recent african ancestry and the recipients of their kidneys, after deceased- and living-donor renal transplantation. for the purposes of apollo, recent african ancestry is defined as individuals with similar genetic make-up to those currently residing in africa. apollo will also study the impact of apol1 rrvs on the health of living kidney donors with recent african ancestry.

Eligibility criteria:
inclusion criteria for living donors: * living kidney donors with self-reported recent african ancestry (defined as african american, afro-caribbean, hispanic black or african) will be eligible for inclusion. exclusion criteria for living donors: * participants who are unable or unwilling to provide informed consent. enrollment and bio sample collection from deceased donors at opos ended on may 31, 2023 and recruiting kidney transplant recipients ended on june 15, 2023. phase ii started on 9/1/2023 and only living donors will be recruited for an additional 2 years.

Keywords: apolopoprotein l1 gene (apol1) kidney transplantation kidney donor united network for organ sharing (unos) association of organ procurement organizations (aopo) kidney transplantation outcomes network
preoperative breast irradiation

Conditions: Breast Cancer

Summary: the probi is a phase i/ii trial assessing the feasibility of preoperative whole breast irradiation in female patients with low to intermediate risk breast cancer, who undergo breast conserving therapy, including a boost dose of irradiation. an additional goal of this study is to assess tumor response to radiotherapy, by imaging modalities (pet-ct and mri) and pathology


Eligibility criteria:
inclusion criteria: * histologically proven invasive breast carcinoma * ct1-2n0 breast cancer * cm0 * female patients ≤ 50 years * planned breast conserving surgery * ability to undergo irradiation and surgery * signed written informed consent exclusion criteria: * prior surgery or radiotherapy for the protocol tumor (neoadjuvant chemotherapy or endocrine therapy is allowed) * planned oncoplastic reduction mammoplasty * ctis * extensive calcifications on mammagram (birads 3,4 or 5) * ct3-4 and/or cn1-3 invasive carcinoma * distant metastasis

Keywords: pre-operative radiotherapy
anterior plate osteosynthesis of fractures of the lower extremity of the radius: does the systematic use of short epiphysic screws limit the posterior protrusion of the screws without compromising stability

Conditions: Fracture; Radius, Lower or Distal End

Summary: anterior plate osteosynthesis of fractures of the lower extremity of the radius may be accompanied by tendinous complications : tenosynovitis of extensors or even tendon ruptures caused by the end of the epiphyseai screws. the intraoperative measurements as well as the realization of the scopic pictures make it possible to estimate the length of the screws but the tendinous lesions remain frequent (5 to 15% according to the various series)

* preoperative consultation * oral information of the patient of the protocol and delivery of the written information note * seeking patient's non-opposition to participating in the study * inclusion of the patient * surgical procedure for distal radius fracture + immediate post-operative radiography * intervention performed according to the usual practices of the service by the surgeon of the day without randomization * radiography: 2 shots: face and wrist profile * control x-ray + consultation * achieved at 3 weeks, 6 weeks and 3 months after the intervention * x-rays: 2 shots: face and wrist profile * control ultrasound o realized at 3 months after the intervention end of participation in the study after consultation of 3 months.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years old * fracture (s) of extra joint distal radius with or without joint refend in the sagitta plane * osteosynthesis by anterior locked plate * patient who did not oppose his participation in this research exclusion criteria: * distal radius fractures with joint refend frontal (posterior marginal)

Keywords: fracture of the radius
treatment of resistant hypertension by renal sympathetic denervation in patients undergoing dialysis therapy

Conditions: Hypertension Secondary to Renal Disease

Summary: the study is designed to investigate the efficacy of renal nerve denervation in treating drug-resistant hypertension in patients with end stage renal disease.

drug resistant hypertension is very common in end stage renal disease treated by dialysis. the prevalence of hypertension has been evaluated to be over 50% and up 80%. in this patient group mortality figures are high because of cardiovascular diseases which are complications of hypertension. renal nerve denervation is a new intervention to treat hypertension. by applying radiofrequency pulses to the renal arteries, the nerves in the vascular wall (adventitia layer) can be denervated. this causes reduction of renal sympathetic afferent and efferent activity and blood pressure can be decreased. the technique and its efficacy in end stage renal disease has not been systematically studied. there are case reports which have showed promising responses to denervation. in the present study 30 patients over 18 years are planned undergo renal denervation if the medical treatment (three different drugs including diuretics) has failed to decrease blood pressure sufficiently(160/100mmhg). the failure of medical treatment will be documented by ambulatory blood pressure measurements. after renal nerve denervation a two year follow-up of patients with ambulatory blood pressure measurements will be organized. the blood pressures before and after denervation are compared and the quality of life of the patients is evaluated by questionnaires.

Eligibility criteria:
inclusion criteria: * patients with end stage renal disease and drug-resistant blood pressure. exclusion criteria: * pregnancy * secondary hypertension * unstable coronary artery disease

Keywords: hypertension end stage renal disease
the blended care intervention "booster" for youth with chronic health conditions to increase fatigue-related self-efficacy

Conditions: Fatigue; Chronic Illnesses

Summary: the goal of this experimental study is to learn if the booster intervention can be used as an early intervention for persistent fatigue. the aim of the intervention is to prevent more fatigue-related disabilities in young people with chronic illnesses like inflammatory bowel disease, childhood cancer, and juvenile idiopathic arthritis by improving self-confidence in managing fatigue (fatigue-related self-efficacy or fse). the main questions this study aims to answer are: * what is the effect of the booster intervention on fatigue-related self-efficacy (fse)? * what is the effect of the booster intervention on fatigue levels, school participation, life satisfaction, and perceived health? * when does improvement in study outcomes happen relative to the booster intervention? * what participant characteristics predict change in study outcomes? participants will follow the booster intervention. booster is a personalised, blended care intervention designed to help young people understand how their thoughts, feelings, and activities impact their fatigue using a smartphone app. the booster app uses experience sampling methodology (esm) to track these fluctuations. based on insights obtained from these data, the participant and their healthcare provider can set personal lifestyle goals, such as increasing physical activity and reducing daytime naps. an earlier version of this intervention, called profeel, was effective in reducing severe fatigue. the investigators have now improved the app to also help with setting and achieving personal goals and monitoring daily progress. the investigators will measure the effect of booster through daily questionnaires during two phases: phase a (baseline, before the goal setting between patient and healthcare provider) and phase b (intervention, starting in the lifestyle change period). the duration of phase a will be randomised for each participant.


Eligibility criteria:
inclusion criteria: * experiencing fatigue for at least 3 months and feeling hindered by it (pediatric short fatigue questionnaire (psfq) score of 15 or higher) * diagnosed with a chronic health condition or treated for childhood cancer exclusion criteria: regarding other treatments: * fatigue fully explained by a somatic or psychiatric diagnosis * chronic health condition unstable in the last 3 months (e.g., recent medication changes or cancer relapse) * significant functional limitations due to fatigue (e.g., more than 50% school absenteeism) regarding feasibility: * cognitive impairment with an estimated iq of below 70 * no smartphone with internet access * unable to speak, read, understand, or write dutch

Keywords: chronic childhood disease fatigue self-efficacy mhealth pediatrics single case
influenza burden assessment in the united kingdom, 1996-2008

Conditions: Influenza

Summary: the study will assess the burden of influenza by age, risk status, vaccination status and influenza subtype, in order to create a complete profile of the burden of influenza-related morbidity and mortality in united kingdom from 1996 to 2008.

this epidemiological study is a modelling of time series retrospectively extracted from multiple databases. the data collection will be a query of existing electronic healthcare databases.

Eligibility criteria:
inclusion criteria: • registration with an acceptable flag in the gprd, or registration with a potentially influenza-related event in the hes database or the ons mortality data. exclusion criteria: -

Keywords: office of national statistics burden of disease influenza hospital episode statistics general practitioners research database
routine screening for eosinophilic esophagitis in patients presenting with dysphagia

Conditions: Dysphagia

Summary: the purpose of this study is to identify the prevalence of pathologic eosinophilic esophagitis (eoe) in the cohort of adult patients who present for specialty care in the gastroenterology clinics with complaint of difficulty swallowing (dysphagia). from this, the investigators will make recommendations regarding routine screening for the diagnosis in this cohort. the prevalence of eoe in patients presenting for specialty care in the gastroenterology clinics with the complaint of dysphagia is great enough that the diagnosis should be routinely screened against in this cohort.


Eligibility criteria:
inclusion criteria: * age \> 18 * complaint of dysphagia exclusion criteria: * pregnancy * age \<18 * on inhaled steroids within the last 30 days * on systemic steroids in the last 30 days * known diagnosis of eosinophilic esophagitis * obvious obstructive etiology found at endoscopy * increased risk of bleeding (on blood thinners or anti-platelet agents other than aspirin)

Keywords: eosinophilic esophagitis
aminolevulinic acid-photodynamic therapy for facial actinic keratosis treatment and prevention

Conditions: Actinic Keratoses

Summary: background actinic keratoses (aks) are often treated separately, lesion by lesion. however, in the past years, aks have been described as a field disease and not limited to single clinically apparent lesions. treatment should therefore target an area of field change which may treat the subclinical aks and reduce the risk of development of further aks, second tumours, and local recurrence. objectives the investigators sought to investigate whether field ala-pdt of facial actinic keratosis would prevent new aks, in comparison with a lesion area receiving the same ala-pdt, in patients with clinical signs of field cancerization. methods eighty patients, previously diagnosed as having aks of the face, were randomized distribution into two groups. 10% aminolaevulinic acid (ala)-pdt for field treatment was on one group and for a lesion area (vehicle control cream was applied to the non-lesion area) was on the other group. during the next 5-year period of follow up, patients were clinically evaluated for new aks.


Eligibility criteria:
inclusion criteria: 1. clinical diagnosed with ak (olsen classification grade i, ii, iii), aged \> 18 years (because no dosing or adverse event data are currently available on the use of topical aminolevulinic acid in patients \<18 years of age, children are excluded from this study); 2. all patients are unfit and reluctant to undergo surgery for any reasons, and volunteered to participate in the study and ability to understand and the willingness to sign a written informed consent. patents are willing to pay for the treatment, and agreed to take a picture of the skin lesions. exclusion criteria: 1. those who had ala-pdt and any other studies that affect this study within 12 weeks ; 2. there are other facial diseases that may affect the efficacy evaluation, such as other photodermatosis; 3. take phototoxic or photosensitizer within 8 weeks; 4. clinical and / or pathological prove that the tumor has invaded other organs or tissues; 5. serious immunocompromised persons; 6. scar constitution; 7. patients are known to have skin photosensitivity, porphyria, or allergies to ala, light or lidocaine; 8. persons are suffering from severe internal diseases, mental and mental illness, infectious diseases or pregnant or lactating women.

Keywords: photodynamic therapy actinic keratoses
study of trametinib and nab-paclitaxel in patients with melanoma

Conditions: Melanoma

Summary: this study will investigate the combination of two drugs, trametinib and nab-paclitaxel, in patients with advanced unresectable or metastatic melanoma. each drug has shown activity in trials of patients with melanoma. however, the combination of these two drugs has not been studied. in this trial the investigators will determine the maximum dose of the drug combination to be administered to patients with advanced unresectable or metastatic melanoma and examine the safety profile of the drug combination.

while treatment for melanoma has evolved in the last few years, advanced/metastatic melanoma remains an aggressive disease with poor prognosis. trametinib and nab-paclitaxel have demonstrated single-agent activity in phase iii trials of patients with melanoma. the investigators propose to investigate this drug combination in patients with advanced unresectable or metastatic melanoma. this open-label phase i study is designed to determine the maximum tolerated dose (mtd), recommended phase ii dose (rp2d), and safety profile of trametinib and nab-paclitaxel given in combination. patients with melanoma and known braf mutation status will receive escalating doses of trametinib and nab-paclitaxel to determine the mtd. once the mtd is determined an additional 6 patients will be treated at the mtd to establish the dose for future studies.

Eligibility criteria:
inclusion criteria: * adults (≥18 years) with histologically or cytologically-confirmed advanced unresectable or metastatic melanoma. braf mutation-positive and wild-type tumors are allowed. * eastern cooperative oncology group (ecog) performance status of 0 or 1 * adequate hematologic, renal, and hepatic function * life expectancy ≥12 weeks * any pre-existing neuropathy must be \<grade 2 per common technology criteria for adverse events (ctcae) version 4.0 exclusion criteria: * more than 1 prior cytotoxic chemotherapy regimen in the metastatic setting * prior mek inhibitor therapy (prior braf inhibitor allowed) * prior nab-paclitaxel (prior taxane allowed) * use of an investigational anti-cancer drug within 21 days or 5 half-lives (whichever is shorter) prior to first dose. a minimum of 10 days after termination of investigational drug is required. any drug-related toxicity should have resolved to grade 1 or baseline. * symptomatic or untreated brain metastases * history of retinal vein occlusion (rvo)

Keywords: trametinib nab-paclitaxel mekinist abraxane unresectable metastatic
prct-study of different non-operative treatment protocols of er-stress negative weber-b unimalleolar ankle fractures.

Conditions: Lateral Malleolus Fractures

Summary: prct multicenter study to evaluate non-operative treatment protocols for treating er-stress negative unimalleolar weber-b type fibular fractures. groups are: 1. 3 weeks in a removable splint 2. 3 weeks in a cast and 3. 6 weeks in a cast. follow-up visits at 3, 6 and 12 weeks and after 1 and 2 years after injury. in each time x-rays laterally and mortise projections. ankle functional outcome questionnaires: olerud-molander score, faos rand-36 and vas in follow up-visits 6 and 12 weeks and 1 and 2 year.

prospective randomized controlled multicenter study to evaluate non-operative treatment protocols for treating er-stress negative unimalleolar weber-b type fibular fractures. groups are: 1. 3 weeks in a removable splint 2. 3 weeks in a cast and 3. 6 weeks in a cast. follow-up visits at 3, 6 and 12 weeks and after 1 and 2 years after injury. in each time x-rays laterally and mortise projections. ankle functional outcome questionnaires: olerud-molander score, faos rand-36 and vas in follow up-visits 6 and 12 weeks and 1 and 2 year.

Eligibility criteria:
inclusion criteria: * stable weber-b type fibula fracture * er-stress negative * 16 or over years old * willingness to participate on study proved by a signature and date * walking without aid before accident * treatment started within 7 days from injury exclusion criteria: * prior ankle fracture or significant fracture in the area of ankle or leg * bilateral ankle fracture * pathological fracture * diabetes mellitus or an other significant periferial neuropathy * municipality of residence in some else catchment area than oulu university hospital or tampere university hospital * patient's understanding or co-operation inadequate

Keywords: er-stress-test negative unimalleolar fibula weber-b fractures
printo (the paediatric rheumatology international trials organisation)

Conditions: Juvenile Idiopathic Arthritis

Summary: a comparison of outcome in children with jia who are in remission on mtx, when mtx is then stopped for either 6 or 12 months


Eligibility criteria:
inclusion criteria: * any child with jia who has gone into remission using methotrexate
protocol for staged stereotactic radiosurgery for large arteriovenous malformations

Conditions: Intracranial Arteriovenous Malformations (AVM)

Summary: stereotactic radiosurgery is a well established treatment option for arteriovenous malformations (avms). the potential complications related to radiosurgery are well documented and are predominately related to radiation effects to the surrounding brain parenchyma. these risks increase with larger lesions, requiring a concommitant reduction in the amount of radiation that can be delivered. this reduction in radiation dose decreases the efficacy of treatment. the broad, long-term objectives of this proposal are 1) to determine the role of fractionated stereotactic radiosurgery in the treatment of large (\>10cc) avms; 2) to evaluate the complication rates related to fractionating these doses compared to conventional stereotactic treatment 3) to evaluate the success rate of treating large avms with this protocol.

this research project will involve performing a preoperative mri and angiogram on patients harboring an avm to determine the feasibility of treating the lesion with gamma knife radiosurgery. patient with lesions greater than 10 cc will be studied. each patient will have a magnetic resonance angiography (mra) with gadolinium and an angiogram immediately before each radiation treatment. if there is a contraindication for mri examination (pacemaker or any other implanted ferromagnetic material), a ct angiogram will be obtained instead. each treatment will be spaced at least 3 months apart. follow-up mris or ct scans will be obtained at 6 month intervals. a follow-up angiogram will be obtained when there is radiographic evidence of complete occlusion based on the mri images, or at 3 years after the procedure, whichever occurs first.

Eligibility criteria:
inclusion criteria: * all patients age 18 or older * inpatients and outpatients, referred for radiosurgical treatment of an arteriovenous malformation * patients with lesions greater than 10 cc, who are currently symptomatic from the avm (hemorrhage, seizure, or ischemia from steal phenomenon) exclusion criteria: * patients without symptoms related to avm